Disclaimer: Compounded PT-141 (bremelanotide) is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This article is for educational purposes only, is not medical advice, and does not establish a provider-patient relationship. Candidacy for any therapy is determined by a licensed provider.
Most conversations about sexual health medications start and end with one class of drug: the PDE5 inhibitors, meaning Viagra, Cialis, and their generics. They work well for many people. But they all do the same thing, mechanically, and for a subset of patients that mechanism simply is not the problem. When the issue is desire rather than blood flow, a drug that only improves blood flow does not address what is actually happening.
That is the clinical context in which PT-141, known generically as bremelanotide, becomes interesting. It works through an entirely different pathway, and understanding that pathway explains both what it can do and who it may be appropriate for.
What PT-141 Actually Is
PT-141 is a synthetic cyclic heptapeptide, meaning a small chain of seven amino acids arranged in a ring. It is an analog of a naturally occurring hormone in the body called alpha-melanocyte-stimulating hormone, or alpha-MSH.[1] It originated from research at the University of Arizona in the 1980s on melanocortin peptides and was subsequently developed as bremelanotide.
The important structural point is that PT-141 was refined to reduce activity at the receptors responsible for skin pigmentation while retaining activity at the receptors in the brain involved in sexual arousal.[1] That selectivity is what makes it a therapeutic candidate rather than a curiosity.
The Mechanism: Brain, Not Blood Vessels
Here is the distinction that matters most, and the one I spend the most time explaining to patients.
PDE5 inhibitors like sildenafil work peripherally. They act on blood vessels, increasing blood flow to genital tissue. They do nothing for desire; they improve the physical response once desire is already present.
PT-141 works centrally, in the brain. It is a melanocortin receptor agonist, meaning it activates a family of receptors called melanocortin receptors. There are five subtypes, and PT-141 acts primarily on two of them, MC3R and MC4R, which are densely expressed in the hypothalamus and limbic system, the brain regions involved in motivation and arousal.[2] The MC4 receptor in particular has been established as a key mediator of centrally regulated sexual arousal.[2]
In practical terms: PDE5 inhibitors address the plumbing. PT-141 acts on the signaling that generates desire in the first place. They are answering two different questions.
What the Research Shows
The peer-reviewed literature on bremelanotide’s mechanism is substantial. Early pharmacology work characterized it as a melanocortin agonist producing dose-dependent effects on sexual response in both preclinical and human studies.[3] Later randomized, placebo-controlled trials in women with sexual arousal and desire concerns supported the central mechanism and led to bremelanotide’s development as an approved product for a specific population.[4]
I want to be precise and honest here, because this is a field crowded with overstatement. Bremelanotide is FDA-approved as a specific branded product for a specific diagnosis in premenopausal women. Compounded PT-141, which is what most telehealth programs including ours provide, is a different thing: it is prepared by a compounding pharmacy, it has not been through FDA review, and its potency and clinical performance cannot be assumed to match the approved product. The underlying peptide and its mechanism are well characterized. The compounded preparation is not the approved drug. Both things are true, and any provider who blurs that line is not being straight with you.
Who the Mechanism Suggests It May Help
Because PT-141 acts on desire pathways rather than blood flow, the patients our physicians evaluate for it are often those for whom PDE5 inhibitors were insufficient or beside the point. Some have tried Viagra or Cialis and found that the physical response improved but the interest did not. Some are dealing with desire concerns where a blood-flow drug was never the right tool.
Candidacy is a clinical decision, not a self-diagnosis. Melanocortin receptors are expressed throughout the body, including in the cardiovascular system, which is why blood pressure and cardiovascular history matter in evaluating whether PT-141 is appropriate. That evaluation is exactly what a licensed provider is for.
The Honest Summary
PT-141 is not a better Viagra. It is a different kind of intervention that happens to address the same broad category of concern from the opposite direction, working on the brain’s arousal signaling rather than on genital blood flow. For the right patient, that difference is the entire point. For the wrong patient, it is not the right tool, and a good provider will tell you so.
If you want to understand whether it fits your situation, that is a conversation for a licensed provider who can review your history. Learn more about our PT-141 therapy program.
References
- Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PubMed: 12851303
- Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. PubMed: 16839319
- Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects. Int J Impot Res. 2004. PubMed: 15833522
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PubMed: 31599840
This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult a licensed provider.